Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Cboe UK • GBp AstraZeneca PLC (AZNL.XC) Follow Add holdings 10,758.00 +162.00 +(1.53%) At close: May 2 at 4:29:58 PM GMT+1 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for AZNL.XC 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: AZNL.XC View More All News Press Releases SEC Filings AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma Here's what top C-suites are saying about tariffs European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2% AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth AstraZeneca’s triple-combo triumphs in two Phase III asthma trials Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma 'Declare victory and move on': Eli Lilly CEO on Trump tariff threat